Dr. Eckardt's Travels

Dr. John Eckardt will be attending the 10th World Conference On Lung Cancer Symposium in Vancouver, Canada on August 12, 2003. The program is sponsored by Glaxo-SmithKline and the educational objectives are as followed.

To discuss goals of treatment and changes in prescribing for the relapsed small cell lung cancer.
To introduce the efficacy and convenience of Oral Hycamtin in the relapsed setting.
To discuss new treatment options of NSCLC and first line SCLC combinations (including Hope Wolf & Noda trials).
To better understand the rationale for weekly treatment with Hycamtin.

Dr. Eckardt will be speaking on the emerging role of weekly chemotherapy in small cell lung cancer.

1/8-12/03—Berlin, Germany-New Strategies in the Treatment of Advance Non-Small Cell Lung Cancer
Speaker: Treatment of lung cancer in the elderly Global launch of Taxotere 1st line
12/12-15/02—Speaking-San Jose- Aventis
Subject: Lung Cancer
12/6-8/02: Glaxo-SKB – Hycamptin Workshop, Florida
Speaker: Global Hycamptin investigator workshop
12/5/02: New York Aventis Training for Reps.
Subject: Lung cancer, helping to train pharmaceutical representatives in discussing new treatment options to physicians.
Nov. 14, 2002: Aventis Oncology Speakers Bureau Meeting, Kingston, PA
Nov. 13-16, 2002: Chemotherapy Foundation Symposium XX, New York City
Nov. 12, 2002: Aventis Speaker Training Meeting: Taxotere in Lung Cancer, New York City
Nov. 9, 2002: Centers of Excellence Symposium at Southeast Missouri Hospital, Cape Girardeau, MO
Oct. 17-18, 2002: Advances in the Treatment of Advanced NSCLC, Great Falls, NY
Oct. 10-11, 2002: New Advances in the Treatment of 2nd Line NSCLC, Las Vegas, NV